Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin (2016 - 2025)

Historic EBT Margin for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 69.79%.

  • Aytu Biopharma's EBT Margin fell 721500.0% to 69.79% in Q4 2025 from the same period last year, while for Dec 2025 it was 38.7%, marking a year-over-year decrease of 347600.0%. This contributed to the annual value of 20.71% for FY2025, which is 47800.0% down from last year.
  • Aytu Biopharma's EBT Margin amounted to 69.79% in Q4 2025, which was down 721500.0% from 14.15% recorded in Q3 2025.
  • Aytu Biopharma's 5-year EBT Margin high stood at 20.69% for Q1 2025, and its period low was 220.22% during Q1 2022.
  • Its 5-year average for EBT Margin is 50.46%, with a median of 28.57% in 2022.
  • As far as peak fluctuations go, Aytu Biopharma's EBT Margin plummeted by -1234500bps in 2021, and later skyrocketed by 1885500bps in 2023.
  • Quarter analysis of 5 years shows Aytu Biopharma's EBT Margin stood at 49.95% in 2021, then skyrocketed by 49bps to 25.47% in 2022, then skyrocketed by 129bps to 7.46% in 2023, then tumbled by -68bps to 2.35% in 2024, then tumbled by -3064bps to 69.79% in 2025.
  • Its last three reported values are 69.79% in Q4 2025, 14.15% for Q3 2025, and 128.46% during Q2 2025.